CANBRIDGE PHARMACEUTICALS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.445 HKD | +1.14% |
|
+39.06% | -55.05% |
| Sales 2023 | 103M 14.2M 111M | Sales 2024 * | 130M 17.94M 140M | Capitalization | 175M 24.15M 189M |
|---|---|---|---|---|---|
| Net income 2023 | -379M -52.31M -409M | Net income 2024 * | -250M -34.5M -270M | EV / Sales 2023 | 3.76 x |
| Net cash position 2023 | 4.44M 612K 4.79M | Net cash position 2024 * | 510M 70.38M 551M | EV / Sales 2024 * | -2.58 x |
| P/E ratio 2023 |
-1.03
x | P/E ratio 2024 * |
-0.7
x | Employees | 100 |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 90% |
More Fundamentals
* Assessed data
More news
Latest transcript on CANbridge Pharmaceuticals Inc.
More press releases
| 1 day | +1.14% | ||
| 1 week | +39.06% | ||
| Current month | +45.90% | ||
| 1 month | +45.90% | ||
| 3 months | -25.83% | ||
| 6 months | -67.75% | ||
| Current year | -55.05% |
1 week
0.32
0.50
1 month
0.300.50
Current year
0.251.09
1 year
0.252.03
3 years
0.259.99
5 years
0.259.99
10 years
0.259.99
| Managers | Title | Age | Since |
|---|---|---|---|
James Xue
CEO | Chief Executive Officer | 55 | 18-01-29 |
Glenn Hassan
DFI | Director of Finance/CFO | 46 | 19-04-01 |
Gerald Cox
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Edward Hu
BRD | Director/Board Member | 61 | 22-07-04 |
James Geraghty
BRD | Director/Board Member | 70 | 18-07-17 |
Peng Kuan Chan
BRD | Director/Board Member | 61 | 21-06-10 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 0.445 | +1.14% | 110,000 |
| 24-04-25 | 0.44 | -6.38% | 196,000 |
| 24-04-24 | 0.47 | -1.05% | 31,000 |
| 24-04-23 | 0.475 | +48.44% | 180,000 |
| 24-04-22 | 0.32 | 0.00% | 0 |
Delayed Quote Hong Kong S.E., April 26, 2024 at 04:08 am EDT
More quotes
CANbridge Pharmaceuticals Inc is a China-based company mainly engaged in the research, development and commercialization of rare disease treatments. The Company's main businesses are the development, production, promotion and sales of medical products. The Company's main product is the glycosylated fusion protein CAN008 for the treatment of glioblastoma (GBM). The Company's products are mainly used in rare diseases such as Hunter's syndrome (MPS II), rare tumors and other fields. The Company is also engaged in the development of gene therapy.
Sector
Pharmaceuticals
Calendar
2024-08-20
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
0.445
HKD
Average target price
7
HKD
Spread / Average Target
+1,473.03%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -55.05% | 23.88M | |
| +5.31% | 69.91B | |
| +10.97% | 9.03B | |
| -16.83% | 4.75B | |
| +43.48% | 4.31B | |
| +3.20% | 3.88B | |
| +18.82% | 2.37B | |
| -21.36% | 2.26B | |
| -29.67% | 2.2B | |
| +8.38% | 1.98B |
- Stock Market
- Equities
- 1228 Stock
